Cargando…
Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer
BACKGROUND: V domain Immunoglobulin suppressor of T cell activation (VISTA) has been proved to be a novel immune checkpoint molecule that positively regulates T cell infiltration in several malignancies. However, the clinical impact of VISTA on muscle-invasive bladder cancer (MIBC) patients remains...
Autores principales: | Li, Wandi, Liu, Zhaopei, Jin, Kaifeng, Shao, Fei, Zeng, Han, Wang, Yiwei, Zhu, Yu, Xu, Le, Wang, Zewei, Chang, Yuan, Zhang, Weijuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347783/ https://www.ncbi.nlm.nih.gov/pubmed/37452272 http://dx.doi.org/10.1186/s12885-023-11157-x |
Ejemplares similares
-
Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients
por: Liu, Chunnan, et al.
Publicado: (2022) -
NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
por: Yan, Sen, et al.
Publicado: (2022) -
Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer
por: Xu, Yijia, et al.
Publicado: (2022) -
Intratumoral CCR5(+) neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responses
por: Xiang, Zhuoyi, et al.
Publicado: (2020) -
Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5(+) CD8(+) T cell abundance
por: Huang, Qiuren, et al.
Publicado: (2020)